The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...